<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605251</url>
  </required_header>
  <id_info>
    <org_study_id>10063030</org_study_id>
    <nct_id>NCT03605251</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.</brief_title>
  <official_title>An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of TAS5315 in combination with
      methotrexate in a 12 week or 36 week in participants with rheumatoid arthritis with
      inadequate response to methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving American College of Rheumatology 20% (ACR20) response</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve ACR20 response</measure>
    <time_frame>Up to Week 36, except for Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving American College of Rheumatology 50% (ACR50) and American College of Rheumatology 70% (ACR70) response</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve DAS28-hs C-ReactivePprotein (CRP) and DAS28-Erythrocyte Sedimentation Rate (ESR) for remission</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28-CRP and DAS28-ESR score</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) for remission</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CDAI and SDAI score</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient assessment score of arthritis pain</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient global assessment score of arthritis</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physician's global assessment score of arthritis</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in modified total sharp score</measure>
    <time_frame>Baseline, Week 2, 4, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Anti-cyclic Citrullinated Peptide antibody levels</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rheumatoid factor levels</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration for TAS5315</measure>
    <time_frame>Baseline, Week 2, 4, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration for TAS5315</measure>
    <time_frame>Baseline, Week 2, 4, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for TAS5315</measure>
    <time_frame>Baseline, Week 2, 4, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and side effects as safety</measure>
    <time_frame>Up to Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>TAS5315 low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS5315 low dose and Methotrexate as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS5315 high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS5315 high dose and Methotrexate as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Methotrexate as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS5315 low dose</intervention_name>
    <description>Oral administration for 12 or 36 weeks</description>
    <arm_group_label>TAS5315 low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS5315 high dose</intervention_name>
    <description>Oral administration for 12 or 36 weeks</description>
    <arm_group_label>TAS5315 high dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of RA according to 2010 ACR/ EULAR rheumatoid arthritis (RA)
             classification criteria

          -  Have been treated with methotrexate (MTX) for at least 90 days prior to screening, and
             must be on a stable dose between 8 and 16 mg/week for at least 56 days prior to
             screening.

          -  Have an inadequate response to MTX

          -  Have a minimum of 6 swollen and 6 tender joints from 66/68 joint count

          -  Have hsCRP of ≥ 0.6 mg/dL

        Exclusion Criteria:

          -  Have been treated with conventional synthetic disease-modifying anti-rheumatic drug,
             except for MTX, within 28 days prior to randomization

          -  Have an inadequate response to biologic disease-modifying anti-rheumatic drug or Have
             been treated with 2 biologic treatment

          -  Have been treated with Janus Kinase inhibitors or other Bruton's Tyrosine Kinase
             inhibitors

          -  Have a positive result for hepatitis B surface antigen/antibody, hepatitis B core
             antibody, hepatitis C virus antibody or human immunodeficiency virus antigen/antibody
             at screening

          -  Have been treated with Oral steroids at dose above 10 mg/day of prednisone or
             prednisone equivalents

          -  Have a diagnosis of Felty's syndrome

          -  Have a positive result of the QuantiFERON®-tuberculosis (TB) Gold test or a T-spot
             ®-TB test at screening

          -  Have a positive result of β-D-glucan at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taiho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

